Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Accendra Health, Inc.NYSE: ACH

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 39.1%

Gross margin was 39.1% in Q1 FY2026, up 19.1 pp from a year earlier. On a trailing-twelve-month basis it was 41.3%, up 15.1 pp year over year. Over 3 fiscal years it widened by 25.2 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
39.1%-1.9 pp QoQ
Last fiscal yearDec 2025
43.5%+22.8 pp YoY
LTMMar 2026
41.3%+15.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+19.1 pp——
1 year+22.8 pp——
3 years+25.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
43.5%
Year-over-year change
+22.8pp

Gross Margin vs competitors

How ACH compares with its peers on the latest reported figures

  • ACH's LTM Mar 2026 gross margin of 41.3% is the 5th highest of the 9 companies compared; the peer median is 58.5%.
  • Its year-over-year change of +15.1 pp is the 3rd highest of 9, against a peer median of +1.2 pp.
  • Over three fiscal years its change of +25.2 pp compares with a peer median of +13.5 pp.
ACH Competitors Peer median
Gross Margin for ACH and competitors
Company Period LTM level YoY 3-year change
BIOABioAge Labs, Inc.LTM Mar 202699.4% -0.6 pp—
SGHTSight Sciences, Inc.LTM Mar 202686.2% +0.5 pp+3.5 pp
CVRXCVRx, Inc.LTM Mar 202685.5% +1.8 pp+7.6 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
ACHAccendra Health, Inc.LTM Mar 202641.3% +15.1 pp+25.2 pp
OMOutset Medical, Inc.LTM Mar 202640.6% +4.7 pp+23.7 pp
CGCCanopy Growth CorporationLTM Mar 202624.9% -4.7 pp+39.2 pp
HITIHigh Tide Inc.LTM Apr 202617.5% -8.3 pp-2.4 pp
EDITEditas Medicine, Inc.LTM Mar 20265.8% +124.1 pp+32.1 pp
ALLOAllogene Therapeutics, Inc.FY2025— ——
CABACabaletta Bio, Inc.FY2025— ——
Peer median (excluding ACH) 58.5%+1.2 pp+13.5 pp

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.79B9.96B10.33B10.7B2.76B
Cost of Revenue8.27B8.13B8.21B8.48B1.56B
Gross Profit1.51B1.83B2.13B2.22B1.2B
Gross Margin15.5%18.3%20.6%20.7%43.5%
Research & Development12.1M0000
Selling, General & Admin1.08B1.55B1.81B1.91B1.05B
Operating Expenses1.14B1.68B2.02B2.43B1.05B
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
EBITDA415.47M368.45M390.57M51.22M364.68M
EBITDA Margin4.2%3.7%3.8%0.5%13.2%
Operating Income368.47M142.91M104.51M(207.77M)150.16M
Operating Margin3.8%1.4%1.0%-1.9%5.4%
Interest Income00000
Interest Expense48.09M128.89M157.92M143.8M129.2M
Other Income / Expenses(91.72M)(132.02M)(159.23M)(149.59M)(252.11M)
Income Before Tax276.75M10.89M(54.73M)(357.36M)(101.95M)
Pre-Tax Margin2.8%0.1%-0.5%-3.3%-3.7%
Income Tax Expense55.17M(11.5M)(13.43M)5.33M729K
Net Income221.59M22.39M(41.3M)(362.69M)(1.1B)
Net Margin2.3%0.2%-0.4%-3.4%-39.8%
EPS (Basic)3.050.30(0.54)(4.73)(14.31)
EPS (Diluted)2.940.29(0.54)(4.73)(14.31)
Weighted Avg Shares72.74M74.5M75.79M76.74M76.9M
Weighted Avg Shares (Diluted)75.49M76.22M75.79M76.74M76.9M

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.